Loading clinical trials...
Loading clinical trials...
First-in-human (FIH), Open-Label, Phase I (Dose Escalation) Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors
Conditions
Interventions
ADG116
Locations
1
United States
NEXT Oncology
San Antonio, Texas, United States
Start Date
August 29, 2019
Primary Completion Date
April 27, 2021
Completion Date
April 27, 2021
Last Updated
September 10, 2021
NCT06898450
NCT05720117
NCT06658951
NCT06625775
NCT05098132
NCT05101070
Lead Sponsor
Adagene Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions